Descripción de la empresa
Pharming Group N.V. operates as a biopharmaceutical entity dedicated to the development and commercialization of protein replacement therapies and precision medicines designed to treat rare diseases across the United States, Europe, and international markets. The company functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a reliance on scientific innovation and regulatory approval processes to bring novel therapeutics to patients. In terms of scale, the organization holds a market capitalization of $1.14B and generates annual revenue of $376.13M, with no specific employee count disclosed in available records. These valuation and revenue figures position the company as a mid-cap entity within the biotechnology landscape, indicating a firm that has achieved significant commercial traction but maintains the operational characteristics often associated with growth-oriented life science companies seeking to expand their pipeline of treatments for rare conditions.
Salud financiera
The company reported a trailing twelve-month revenue of $376.13M alongside a net income of $2.85M and an EBITDA of $43.46M, revealing a substantial gap between top-line generation and bottom-line profitability that highlights a cost structure dominated by research, development, or high operating expenses typical in the early stages of commercializing complex biologics. While the net income figure appears modest relative to revenue, the EBITDA provides a clearer picture of operational cash generation before non-cash expenses, suggesting that the core business operations are generating significant earnings before interest, taxes, depreciation, and amortization. The firm demonstrates robust financial flexibility with free cash flow reaching $63.69M, which significantly exceeds the net income and indicates strong cash conversion efficiency that can be utilized for reinvestment or debt repayment. Profitability analysis shows a gross margin of 87.9%, reflecting the high value and low direct cost of goods associated with biopharmaceutical products, while the operating margin sits at 5.8% and the profit margin at 0.8%, indicating that significant operating expenses are eroding the gross profit before reaching the net bottom line. Liquidity and leverage metrics show the company holds $179.10M in cash against $115.78M in debt, resulting in a debt-to-equity ratio of 41.78, which suggests a balance sheet that is leveraged but maintains a conservative posture given the substantial cash buffer. Short-term liquidity is further supported by a current ratio of 2.59, indicating that the company possesses more than double the current assets necessary to cover its current liabilities without needing to raise external capital. Return metrics reveal a return on equity of 1.0% and a return on assets of 4.5%, figures that suggest management effectiveness is currently constrained by the capital-intensive nature of the business or the specific accounting treatment of development costs, rather than reflecting an inability to generate value.
Evaluación de valoración
Valuation metrics indicate a premium pricing structure with a trailing P/E ratio of 407.75 and a forward P/E of 402.72, a negligible difference between the two figures that implies the market expects earnings growth to track closely with current profitability levels rather than a dramatic expansion in the near term. The price-to-book ratio stands at 39.02, signaling a substantial market premium over the company's book value, which is characteristic of biotechnology firms where intangible assets, intellectual property, and future pipeline potential are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 3.02 and an EV/EBITDA of 247.18 further underscore that the stock is priced based on future growth expectations and asset light characteristics rather than current earnings power. Price momentum data shows a 52-week high of $21.34 and a 52-week low of $7.50, meaning the current trading price sits at a specific point within this wide range that reflects recent market sentiment volatility. The stock exhibits a beta of 0.16, indicating that its price volatility is significantly lower than the broader market, suggesting the share price moves independently of general market swings and is driven more by specific company developments or sector-specific factors.
Growth & Income
Growth dynamics are highlighted by a revenue growth rate of 14.9% year-over-year and an earnings growth rate of 98.1% year-over-year, demonstrating that earnings are expanding at a pace nearly seven times faster than revenue, which implies significant margin expansion or one-time income recognition events impacting the net income figure disproportionately. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm does not distribute earnings to shareholders but instead retains all profits to fuel internal growth initiatives, research programs, or balance sheet strengthening. This retention strategy is consistent with the life science sector's requirement for continuous capital investment to maintain regulatory compliance and advance clinical trials. Overall, the company presents a growth-oriented profile characterized by high revenue expansion and explosive earnings growth, coupled with a zero-dividend policy that prioritizes capital allocation toward long-term value creation over immediate income distribution to investors.